Meinolf Karthaus - Concepedia

Author

Meinolf Karthaus

Also Known As

Andreas Groll, Fabio Guolo, François Blot, Karthaus M, Karthaus M., Karthaus, Meinolf, M Karthaus, M. Karthaus, M., Karthaus, Meinolf Karthaus

324

Publications

8.2K

Citations

H-Index

Concepts

All Affiliations

München Klinik Neuperlach Charité - Universitätsmedizin Berlin Heidelberg University University Hospital Heidelberg University of Cologne

About

Meinolf Karthaus is an author at München Klinik Neuperlach specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	38	3.4K
2	Health Sciences	5	5	288
3	Allergy	3	3	158
4	Clinical Immunology	2	2	91
5	Epidemiology	1	1	13

Meinolf Karthaus

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial Johan Maertens, Issam Raad, Kieren A. Marr, The Lancet Antifungal AgentIsavuconazole Versus VoriconazoleAntifungal AgentsFungal BiologyNon-inferiority Trial	2015	938
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type <i>KRAS</i> Exon 2 Metastatic Colorectal Cancer Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus, Journal of Clinical Oncology	2014	623
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial Johan Maertens, Galia Rahav, Dong‐Gun Lee, The Lancet Invasive AspergillosisPosaconazole Versus VoriconazoleAntifungal AgentAntifungal AgentsMedicinal Fungi	2021	257
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program Armando Santoro, Mary O’Brien, Rolf A. Stahel, Journal of Thoracic Oncology Chemonaïve PatientsMalignant Pleural MesotheliomaMedicinePathologyPleural Disease	2008	247
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial Meinolf Karthaus, Albrecht Kretzschmar, H. Kröning, Annals of Oncology Venous DiseaseOncologyVenous ThrombosisCentral Venous CathetersPatient Safety	2005	219
Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology Oliver A. Cornely, Angelika Böhme, Dieter Buchheidt, Haematologica Antifungal AgentFluconazole 400German SocietyPrimary ProphylaxisAntifungal Agents	2008	178
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma Fernando Rivera, Meinolf Karthaus, J. Randolph Hecht, International Journal of Colorectal Disease	2017	132
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion Karin Potthoff, Ralf‐Dieter Hofheinz, Jessica C. Hassel, Annals of Oncology MedicineCutaneous BiologyInterdisciplinary ManagementClinical DermatologyTranslational Research	2010	128
Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, Annals of Hematology Diagnostic MycologyOncologyGerman SocietyCancer Patients—recommendationsInvasive Fungal Infections	2008	121
Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Journal of Clinical Oncology	2022	120

Page 1